Logo image
Back
Impact of Dietary Potassium Restrictions in CKD on Clinical Outcomes: Benefits of a Plant-Based Diet
Journal article   Open access   Peer reviewed

Impact of Dietary Potassium Restrictions in CKD on Clinical Outcomes: Benefits of a Plant-Based Diet

Deborah J. Clegg, Samuel A. Headley and Michael J. Germain
Kidney medicine, v 2(4), pp 476-487
15 Jun 2020
DOI: https://doi.org/10.1016/j.xkme.2020.04.007
PMID: 32775988
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
http://www.kidneymedicinejournal.org/article/S2590059520301096/pdfView
Published, Version of Record (VoR) Open
url
https://doi.org/10.1016/j.xkme.2020.04.007View
Published, Version of Record (VoR) Open

Abstract

Chronic kidney disease hyperkalemia patiromer plant-based diet potassium potassium-binder renin-angiotensin-aldosterone system inhibitor Review sodium zirconium cyclosilicate
In patients with advanced-stage chronic kidney disease (CKD), progressive kidney function decline leads to increased risk for hyperkalemia (serum potassium > 5.0 or >5.5 mEq/L). Medications such as renin-angiotensin-aldosterone system inhibitors pose an additional hyperkalemia risk, especially in patients with CKD. When hyperkalemia develops, clinicians often recommend a diet that is lower in potassium content. This review discusses the barriers to adherence to a low-potassium diet and the impact of dietary restrictions on adverse clinical outcomes. Accumulating evidence indicates that a diet that incorporates potassium-rich foods has multiple health benefits, which may also be attributable to the other vitamin, mineral, and fiber content of potassium-rich foods. These benefits include blood pressure reductions and reduced risks for cardiovascular disease and stroke. High-potassium foods may also prevent CKD progression and reduce mortality risk in patients with CKD. Adjunctive treatment with the newer potassium-binding agents, patiromer and sodium zirconium cyclosilicate, may allow for optimal renin-angiotensin-aldosterone system inhibitor therapy in patients with CKD and hyperkalemia, potentially making it possible for patients with CKD and hyperkalemia to liberalize their diet. This may allow them the health benefits of a high-potassium diet without the increased risk for hyperkalemia, although further studies are needed.

Metrics

16 Record Views
47 citations in Web of Science
48 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Urology & Nephrology
Logo image